
Release date: 2026-01-09 16:42:42 Article From: Lucius Laos Recommended: 75
Capmatinib is indicated for the treatment of lung cancer. Its mechanism of action is to block a protein that causes cancer cell growth and proliferation, thereby helping to slow down or prevent the spread of cancer cells.
Your healthcare provider can test your cancer to determine if it is likely to respond to Tabrecta. Tabrecta is a specific type of medication known as a kinase inhibitor. Kinases are proteins responsible for sending and receiving signals in the body. These signals help your cells perform essential functions such as normal growth. Tabrecta blocks a specific kinase in the body called mesenchymal-epithelial transition factor (MET). In some cancers, MET undergoes mutations, leading to the uncontrolled growth of cancer cells. By blocking the signals sent by MET or its mutated forms, Tabrecta helps inhibit cancer cell growth and proliferation, which may result in tumor shrinkage.
You need to inform your doctor if you have any of the following conditions:
1. Liver disease.
2. Lung or respiratory diseases, such as asthma or chronic obstructive pulmonary disease (COPD).
3. Pancreatic disease.
4. A history of abnormal reactions or allergies to capmatinib, other medications, foods, dyes, or preservatives.
5. Being pregnant or planning to become pregnant.
6. Breastfeeding.
1. Take this medication orally with warm water. Follow the instructions on the prescription label and take it at the same time each day. Do not cut, crush, or chew the tablets; swallow them whole. It can be taken with or without food. If it causes stomach discomfort, take it with meals.
2. If side effects occur, your medical team may adjust your dosage or advise you to stop taking the medication. Do not change the dosage or discontinue the drug on your own unless instructed by your medical team.
3. Do not drink grapefruit juice while taking this medication.
4. Consult your medical team regarding the use of this drug in children. Special precautions may be required.
5. If you suspect an overdose, contact a poison control center or emergency room immediately.
6. Capmatinib is for your personal use only. Do not share it with others.
7. If you miss a dose, skip the missed dose and take your regular dose at the next scheduled time. Do not take an extra dose or double the dose to make up for the missed one.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1712025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1872025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1672025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1622025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: